Continuum Advisory LLC Sells 59 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Continuum Advisory LLC trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,824 shares of the medical research company’s stock after selling 59 shares during the period. Continuum Advisory LLC’s holdings in Thermo Fisher Scientific were worth $1,217,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC raised its position in shares of Thermo Fisher Scientific by 1.9% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 799 shares of the medical research company’s stock valued at $457,000 after acquiring an additional 15 shares during the period. Karp Capital Management Corp raised its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Karp Capital Management Corp now owns 3,195 shares of the medical research company’s stock worth $2,132,000 after buying an additional 17 shares during the period. Archer Investment Corp raised its holdings in Thermo Fisher Scientific by 1.3% during the 4th quarter. Archer Investment Corp now owns 1,317 shares of the medical research company’s stock worth $879,000 after buying an additional 17 shares during the period. Deseret Mutual Benefit Administrators raised its holdings in Thermo Fisher Scientific by 2.7% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 647 shares of the medical research company’s stock worth $432,000 after buying an additional 17 shares during the period. Finally, Mechanics Bank Trust Department raised its holdings in Thermo Fisher Scientific by 0.9% during the 4th quarter. Mechanics Bank Trust Department now owns 1,963 shares of the medical research company’s stock worth $1,310,000 after buying an additional 18 shares during the period. Institutional investors and hedge funds own 87.48% of the company’s stock.

In other news, COO Michel Lagarde sold 17,150 shares of the business’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following the sale, the chief operating officer now directly owns 15,758 shares in the company, valued at $8,640,111.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 2,181 shares of the business’s stock in a transaction dated Wednesday, May 4th. The stock was sold at an average price of $562.46, for a total value of $1,226,725.26. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at $103,139,977.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,531 shares of company stock worth $16,194,942. Company insiders own 0.43% of the company’s stock.

Several equities analysts have recently weighed in on TMO shares. StockNews.com started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They set a “hold” rating for the company. BTIG Research reissued a “buy” rating and issued a $718.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, February 3rd. Finally, Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $605.00 to $525.00 in a research note on Monday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $647.00.

TMO stock traded up $28.76 during midday trading on Friday, reaching $568.87. The company had a trading volume of 40,758 shares, compared to its average volume of 1,620,813. The company has a market capitalization of $222.69 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 1.87 and a beta of 0.83. The stock has a 50 day moving average price of $563.37 and a 200-day moving average price of $588.02. Thermo Fisher Scientific Inc. has a 1-year low of $438.72 and a 1-year high of $672.34. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last posted its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 EPS for the quarter, beating analysts’ consensus estimates of $6.17 by $1.08. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The business had revenue of $11.82 billion during the quarter, compared to the consensus estimate of $10.66 billion. During the same quarter in the previous year, the firm earned $7.21 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.69 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Shareholders of record on Wednesday, June 15th will be given a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date of this dividend is Tuesday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.26%.

Thermo Fisher Scientific Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.